Cedars-Sinai Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cedars-Sinai Medical Center sits in the top decile of US sponsors by registered trial count (#106 of 15,742 sponsors by registered trial count).
Cedars-Sinai Medical Center: 339 sponsored US clinical trials, 70 recruiting.
Cedars-Sinai Medical Center sponsors 339 registered US clinical trials on ClinicalTrials.gov, 70 of them currently recruiting, and 180 completed. 42 of these trials are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Cancer, with 6 trials.
Top-decile sponsor footprint
Cedars-Sinai Medical Center ranks in the top decile of sponsors by registered trial count (#106 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
180 of 230 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
339 total, page 2 of 7
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
NCT04442724
Capillary Endoscopy Aspiration Catheter
NCT04418258
The Role of Virtual Reality During Regional Anesthesia
NCT04163809
Stem Cell Transplantation in Crohn's Disease
NCT04224558
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
NCT03876223
The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study
NCT03910569
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
NCT03774446
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
NCT03504956
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
NCT03193541
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
NCT03193515
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
NCT02910180
Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry
NCT03836521
Active Surveillance of Papillary Thyroid Microcarcinoma
NCT02609685
WISE CVD - Continuation (WISE HFpEF)
NCT02582021
Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation
NCT02318342
Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease
NCT02301663
Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery
NCT02316275
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
NCT00573339
Heart Disease of the Small Arteries in Women and Men
NCT00573027
Pituitary Tumor Surveillance: Pathogenic Correlation
NCT00599092
Population Health Approach to Optimizing Medications in Older Adults
NCT06110156
Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand
NCT05747469
A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
NCT05692323
Atezolizumab for Idiopathic Pulmonary Fibrosis
NCT05515627
Terazosin and Parkinson's Disease Extension Study
NCT05109364
DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors
NCT05462041
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
NCT05306457
A Diagnostic for the Early Detection of Bladder Cancer
NCT05347342
CNS10-NPC for the Treatment of RP
NCT04284293
Digitally Captured Activity Data and PROs to Monitor Physical Function in Prostate Cancer Patients
NCT04575402
Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer
NCT04502407
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
NCT04386317
Cardiac Changes in Early Parkinson's Disease: A Follow up Study
NCT04218968
Pharmacist Intervention to Reduce Post-Hospitalization Utilization
NCT04071951
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
NCT03859388
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients
NCT03757182
Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
NCT03163368
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
NCT03193528
Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT02564848
Beauty from Within Community Screening Project
NCT02588690
Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction
NCT00832702
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
NCT00921609
Online Pain Education for Crohn's Disease and Ulcerative Colitis
NCT07671313
VR Pilot for Pancreatitis
NCT06362187
Debriefing Consult for Psychiatric Symptoms After Severe Maternal Morbidity
NCT07684521
SAMe in Prevention of Oxaliplatin-associated Liver Injury
NCT06258525
TAVR vs SAVR in Severe Bicuspid Aortic Stenosis
NCT07413965
Active vs. Passive VR During Office-based ENT Procedures
NCT07599826
Empowered Relief Study
NCT07562750
Together-Breast Cancer Support Platform
NCT07499089
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 40 |
| Phase 3 | 9 |
| Phase 4 | 33 |
What is open in the Cedars-Sinai Medical Center pipeline
70 recruiting of 339 indexed (21% open); 180 completed (53%).
Phase mix: 42 late (III/IV) vs 83 early (I/II) (early-phase heavy).
Top condition: Bladder Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cedars-Sinai Medical Center: open-pipeline peers nationwide
Peers matched on 339 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
Cedars-Sinai Medical Center sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 339 trials (± recruiting share)
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
Sponsors near 21% open enrollment (± trial volume)
- University of Colorado, Denver · 21% recruiting · 1,283 trials
- Craig Hospital · 21% recruiting · 29 trials
- W.L.Gore & Associates · 21% recruiting · 53 trials
- Georgia Institute of Technology · 21% recruiting · 24 trials
Related
What to do with this Cedars-Sinai Medical Center page
339 registered trials is a research-attention snapshot, not an endorsement of Cedars-Sinai Medical Center or any single study.
- 70 of Cedars-Sinai Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bladder Cancer is the condition Cedars-Sinai Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cedars-Sinai Medical Center pipeline card: 339 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.